[Skip to Content]
[Skip to Content Landing]
Views 282
Citations 0
Translational Science With Clinical Promise
March 2013

Recombinant T-Cell Receptor Ligands in the Treatment of Uveitis

Author Affiliations

Author Affiliation: Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark, New Jersey.

JAMA Ophthalmol. 2013;131(3):399-400. doi:10.1001/jamaophthalmol.2013.111

Uveitis is a major cause of blindness worldwide. Typically, topical and/or systemic corticosteroids are used for the initial treatment of uveitis, but local and systemic adverse effects (eg, cataract, glaucoma, adrenal suppression, and hyperglycemia) may limit long-term use. Alternative immunomodulatory agents include antimetabolites (eg, azathioprine, methotrexate, and mycophenolate mofetil), alkylating agents (eg, cyclophosphamide and chlorambucil), T-cell inhibitors (eg, cyclosporine and tacrolimus), and cytokine inhibitors (eg, infliximab, which blocks tumor necrosis factor-α, and daclizumab, which blocks interleukin-2R). These agents are quite effective, but they too can be associated with serious adverse effects (eg, pancytopenia, hemorrhagic cystitis, opportunistic infections, and lymphoma).

First Page Preview View Large
First page PDF preview
First page PDF preview